InflaRx shares jumped 22% on May 6, 2026 after announcing Phase 2 planning for oral C5a inhibitor izicopan in ANCA-associated vasculitis.
The company will pursue studies in aHUS, IgA nephropathy and C3 glomerulopathy, with data next year and a PK study in China.
InflaRx priced an offering of 75 million shares at $2.00, closing May 7, with participation from TCGX, Farallon, Sirenia, Columbia Threadneedle and Great Point.
Funds are projected to support milestones through 2029, and a Capital Markets Day and webcast are scheduled for May 8 and summer 2026.